Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 80 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abatacept, rituximab or tocilizumab (Truximab, TRUXIMA) | 3件: Abatacept Abatacept,Rituximab (Truxima), Tocilizumab | 3件: Tocilizumab
Tocilizumab
,Rituximab (Truximab, TRUXIMA), Abatacept 💬 1. Abatacept, rituximab or tocilizumab
| 4件: CD80 CD80,CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - ... | 1件: 46 46 💬1. Abatacept, rituximab or tocilizumab
| ||||||||||||||||
| 2 | ABP 798 - Biosimilar to rituximab (Truximab, TRUXIMA) | 1件: Rituximab Rituximab (Truxima) | 1件: Rituximab
Rituximab
(Truximab, TRUXIMA) 💬2. ABP 798 - Biosimilar to rituximab
| 1件: MS4A1 MS4A1 💬2. ABP 798 - Biosimilar to rituximab
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬2. ABP 798 - Biosimilar to rituximab
| ||||||||||||||||
| 3 | ABP 798 Biosimilar to Rituximab (Truximab, TRUXIMA) | 1件: Rituximab Rituximab (Truxima) | 1件: Rituximab
Rituximab
(Truximab, TRUXIMA) 💬3. ABP 798 Biosimilar to Rituximab
| 1件: MS4A1 MS4A1 💬3. ABP 798 Biosimilar to Rituximab
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬3. ABP 798 Biosimilar to Rituximab
| ||||||||||||||||
| 4 | Administration of rituximab and methylprednisolone (Truximab, TRUXIMA) | 2件: Methylprednisolone Methylprednisolone,Rituximab (Truxima) | 2件: Methylprednisolone
Methylprednisolone
,Rituximab (Truximab, TRUXIMA) 💬 4. Administration of rituximab and methylprednisolone
| 2件: MS4A1 MS4A1,NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 51 51 💬4. Administration of rituximab and methylprednisolone
| ||||||||||||||||
| 5 | Alemtuzumab and Rituximab (Truximab, TRUXIMA) | 2件: Alemtuzumab Alemtuzumab,Rituximab (Truxima) | 2件: Alemtuzumab
Alemtuzumab
,Rituximab (Truximab, TRUXIMA) 💬 5. Alemtuzumab and Rituximab
| 2件: CD52 CD52,MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 60 60 💬5. Alemtuzumab and Rituximab
| ||||||||||||||||
| 6 | Alemtuzumab, Rituximab (Truximab, TRUXIMA) | 2件: Alemtuzumab Alemtuzumab,Rituximab (Truxima) | 2件: Alemtuzumab
Alemtuzumab
,Rituximab (Truximab, TRUXIMA) 💬 6. Alemtuzumab, Rituximab
| 2件: CD52 CD52,MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 63 63 💬6. Alemtuzumab, Rituximab
| ||||||||||||||||
| 7 | Anti-CD20 B cell depletion with Truxima | - | - | - | - | 1件: 49 49 💬7. Anti-CD20 B cell depletion with Truxima
| ||||||||||||||||
| 8 | Belimumab in SLE patients / Rituximab in RA patients (Truximab, TRUXIMA) | 2件: Belimumab Belimumab,Rituximab (Truxima) | 2件: Rituximab
Rituximab
(Truximab, TRUXIMA),Belimumab 💬 8. Belimumab in SLE patients / Rituximab in RA patients
| 2件: MS4A1 MS4A1,TNFSF13B 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network fo ... | 2件: 46 46, 49 💬
| ||||||||||||||||
| 9 | Bendamustine, Rituximab (Truximab, TRUXIMA) | 2件: Bendamustine Bendamustine,Rituximab (Truxima) | 2件: Rituximab
Rituximab
(Truximab, TRUXIMA),Bendamustine 💬 9. Bendamustine, Rituximab
| 1件: MS4A1 MS4A1 💬9. Bendamustine, Rituximab
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 61 61 💬9. Bendamustine, Rituximab
| ||||||||||||||||
| 10 | Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine (Truximab, TRUXIMA) Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine (Truximab, TRUX ... | 3件: Azathioprine Azathioprine,Dexamethasone, Rituximab (Truxima) | 3件: Azathioprine
Azathioprine
,Dexamethasone , Rituximab (Truximab, TRUXIMA) 💬 10. Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
| 2件: MS4A1 MS4A1,NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬10. Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
|